Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

BY Benzinga
— 4:06 PM ET 05/11/2022
  • According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc NYSE:EBS might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards.
  • Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. 
  • "Despite major red flags at its vaccine manufacturing facility, Emergent's executives swept these problems under the rug and continued to rake in taxpayer dollars," Rep. Carolyn Maloney said.
  • Emergent hid the evidence, the report alleges, by removing quality-assurance hold tags from Johnson & Johnson NYSE: JNJ COVID-19 shot batches that indicated that the containers had quality issues.
  • Related: Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters.
  • The report also says that Emergent entered contracts with the two companies despite knowing that technical operations were not up to snuff for at least a few years.
  • The CDMO maintains that it never knowingly misled the FDA or any partners involved in the manufacturing process. 
  • The report says that President Donald Trump's administration was aware of deficiencies highlighted at the Bayview site when it received $628 million in funding in May 2020. 
  • AstraZeneca Plc NASDAQ:AZN personnel raised concerns to Emergent in July of 2020.
  • The report also found that inexperienced staff and the high turnover led to vaccine contamination.
  • Price Action: EBS shares are down 8.03% at $27.96 on Wednesday.
  • Image by torstensimon from Pixabay

More JNJ News

  • J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business
    Reuters - 6:37 AM ET 05/11/2022
  • BRIEF-Johnson & Johnson Appoints Thibaut Mongon As CEO Designate Of Planned New Consumer Health Company
    Reuters - 6:32 AM ET 05/11/2022
  • J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business
    Reuters - 6:30 AM ET 05/11/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close